Gilead Sciences is a corporate/pharmaceutical funder whose philanthropic activity centers on advancing diagnosis, treatment, prevention and equitable access for viral diseases (especially HIV and viral hepatitis), emerging infectious diseases, and related community health needs. They support a mix of clinical research, public health programs, community-based organizations serving marginalized populations (including LGBTQ+ people and people who use drugs), and capacity-building efforts that improve care delivery and linkage to treatment. Gilead gives both domestically and globally and often coordinates grants with programmatic partnerships, product donations, and targeted initiatives in crisis response and health equity.
Combination of programmatic initiative grants and partnerships (including RFP-driven and invitation-only programs), philanthropic foundation grants, in-kind product donations, and awards/support for clinical research; funding ranges from small community grants to multi-year, larger institutional awards and is focused around defined programs and campaigns rather than open unrestricted funding.
Regístrate gratis para ver qué tan bien se adapta tu organización sin fines de lucro a este financiador, obtener un pitch generado por IA y descubrir fundaciones similares.
Check Gilead and Gilead Foundation program pages for current initiatives and RFPs, align proposals with their priorities (HIV, HCV, harm reduction, health equity), emphasize measurable outcomes and partnerships with clinical providers, and expect program-specific eligibility or invitation processes rather than unsolicited unrestricted general grants.
Financiamiento actual y próximo de Gilead Sciences, Inc. al que tu organización sin fines de lucro podría postularse.
¿Quién puede postularse? LOIs should address one or more listed AmBisome topic areas and be submitted in Gilead OPTICS by June 30, 2026.
Fecha límite: LOIs received by June 30, 2026
¿Quién puede postularse? Concepts must address implementation of updated HBV treatment guidelines and shared-decision making; concepts proposing only new HBV testing will not be considered.
Fecha límite: Rolling until funds are exhausted
¿Quién puede postularse? Concepts should focus on models of care supporting informed treatment initiation for HCV-positive pregnant patients, including post-treatment follow-up and postpartum outcomes.
Fecha límite: Rolling until funds are exhausted
¿Quién puede postularse? Concepts should evaluate reflex or double-reflex HDV testing and linkage-to-care strategies in HBsAg-positive populations and address care cascade gaps.
Fecha límite: Ongoing evaluation; no fixed deadline stated
Fecha límite: LOI due July 12, 2026.
Haz seguimiento de estas fechas límite, recibe recordatorios y descubre qué tan bien encaja tu organización — gratis con una cuenta de Kindora.
Crea una cuenta gratisLas fechas límite y los requisitos de elegibilidad son un resumen de fuentes públicas y pueden cambiar — confirma siempre los detalles en la página oficial de solicitud del financiador antes de postularte.